Literature DB >> 7751409

Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone.

A el-Yazigi1, K Chaleby, A Gad, D A Raines.   

Abstract

The steady-state kinetics of amitriptyline (AMI), fluoxetine (FLU), and their active metabolites nortriptyline (NTRIP) and norfluoxetine (NFLU) were studied in 15 patients treated once daily for long durations with 50 mg of AMI and 20 mg of FLU. These compounds were analyzed simultaneously in plasma by liquid chromatography. The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively. The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17). There was a significant correlation (P < 0.05) between Css of FLU and that of AMI or NTRIP. The Css and Css(m)/Css values obtained for AMI were higher (P < 0.056 and P < 0.0034, respectively) than those we observed in 10 patients treated solely with the same dose of AMI. The twofold increase in Css of AMI and ninefold increase in Css of NTRIP seem to be the result of inhibition of the metabolism of these compounds by FLU, particularly the ring hydroxylation. Norfluoxetine may have a small inhibitory influence on the metabolism of NTRIP but lacks this effect on the metabolism of AMI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751409     DOI: 10.1002/j.1552-4604.1995.tb04740.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

1.  Ritonavir-fluoxetine interaction.

Authors:  S Eralp Bellibas
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

3.  Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Authors:  Michel Tod; Christina Nkoud-Mongo; François Gueyffier
Journal:  AAPS J       Date:  2013-09-12       Impact factor: 4.009

4.  Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Authors:  Michel Tod; Sylvain Goutelle; Fannie Clavel-Grabit; Grégoire Nicolas; Bruno Charpiat
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

Review 5.  Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Authors:  J K Hicks; J J Swen; C F Thorn; K Sangkuhl; E D Kharasch; V L Ellingrod; T C Skaar; D J Müller; A Gaedigk; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2013-01-16       Impact factor: 6.875

Review 6.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 7.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

8.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Authors:  J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2017-02-13       Impact factor: 6.875

Review 9.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

10.  Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies.

Authors:  Espen Molden; Beate Hennie Garcia; Pia Braathen; Anne Elise Eggen
Journal:  Eur J Clin Pharmacol       Date:  2005-02-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.